摘要
目的：研究替吉奥联合奥沙利铂方案（SOX）治疗进展期胃癌的远期效果及安全性。方法选取本院收治的进展期胃癌患者70例，按照随机数字法分为观察组和对照组，每组35例。观察组患者给予SOX联合化疗，对照组患者给予奥沙利铂（OXA）、亚《酸钙（CF）和氟尿嘧啶（FOLFOX6）方案进行化疗治疗，比较两组的化疗效果、进展期胃癌p-p53、p21及pATM基因表达率、围术期指标、疾病进展生存时间、中位生存时间及不良反应发生情况。结果观察组的化疗有效率为45.7%，与对照组的40.0%比较，差异无统计学意义（P〉0.05）；两组的进展期胃癌p-p53、p21及pATM基因表达率及围术期指标比较，差异无统计学意义（P跃0.05）；观察组的疾病进展时间、中位生存时间显著长于对照组（P〈0.05）；两组化疗后均出现白细胞减少、肝肾损害等不良反应，差异无统计学意义（P跃0.05）。结论替吉奥联合奥沙利铂化疗方案治疗进展期胃癌的远期效果较好，化疗不良反应患者可耐受，且芋~郁级白细胞减少发生率较低，生存时间延长，临床应用价值显著。
Objective To study the long-term effect and safety of tegafur, gimeracil and oteracil potassium combined with oxaliplatin （SOX） in the treatment of advanced gastric carcinoma. Methods 70 patients with advanced gastric car-cinoma admitted into our hospital were selected and evenly divided into the observation group and control group ac-cording to the random number method.The observation group was treated with SOX combined chemotherapy,while the control group was treated with the FOLFOX6 regimen of oxaliplatin （OXA）,calcium folinate （CF）,and fluorouracil,the effect of chemotherapy,the expression rate of p-p53,p21,and pATM gene in advanced gastric carcinoma,perioperative index,and survival time in the progression of disease,and mean survival time,and the incidence of adverse reaction in the two groups were compared. Results In the observation group,the effective rate of chemotherapy was 45.7%,while in the control group,it was 40.0%,which didn’t display a statistical difference （P〉0.05）.There was no statistical difference in genetic expression rate of p-p53,p21,and pATM in advanced gastric carcinoma as well as perioperative index （P〉0.05）.The survival time in the progression of disease and mean survival time in the observation group were remarkably longer than those in the control group with statistical differences （P〈0.05）.After chemotherapy,adverse reaction of leukopenia and injury of the liver and kidney and so on doccurred in both groups,which didn’t show statistical differ-ence （P〉0.05）. Conclusion Chemotherapy regimen of tegafur,gimeracil and oteracil potassium combined with oxaliplatin in the treatment of advanced gastric carcinoma can obtain a long-term effect having tolerant adverse reaction due to chemotherapy for patients with lower incidence rate of leukopenia in classificationⅢ-Ⅳ,and prolonged survival time.It has a remarkable clinical application value.
出处
《中国当代医药》
2015年第7期109-111,113,共4页
China Modern Medicine
关键词
进展期胃癌
替吉奥
奥沙利铂
Advanced gastric carcinoma
Tegafur,gimeracil and oteracil potassium capsule
Oxaliplatin
